-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Pneumonia -X- _ O
is -X- _ O
among -X- _ O
the -X- _ O
main -X- _ O
causes -X- _ O
of -X- _ O
illness -X- _ O
and -X- _ O
death -X- _ O
in -X- _ O
children -X- _ O
< -X- _ O
5 -X- _ O
years -X- _ O
of -X- _ O
age. -X- _ O
There -X- _ O
is -X- _ O
a -X- _ O
need -X- _ O
to -X- _ O
better -X- _ O
describe -X- _ O
the -X- _ O
epidemiology -X- _ O
of -X- _ O
viral -X- _ B-Patient
community-acquired -X- _ I-Patient
pneumonia -X- _ I-Patient
( -X- _ O
CAP -X- _ O
) -X- _ O
in -X- _ O
developing -X- _ O
countries. -X- _ O
METHODS -X- _ O
: -X- _ O
From -X- _ O
July -X- _ O
2004 -X- _ O
to -X- _ O
June -X- _ O
2007 -X- _ O
, -X- _ O
we -X- _ O
examined -X- _ O
nasopharyngeal -X- _ O
aspirates -X- _ O
( -X- _ O
NPA -X- _ O
) -X- _ O
from -X- _ O
2,230 -X- _ O
cases -X- _ O
of -X- _ O
pneumonia -X- _ B-Patient
( -X- _ O
World -X- _ O
Health -X- _ O
Organization -X- _ O
criteria -X- _ O
) -X- _ O
in -X- _ O
children -X- _ B-Patient
2 -X- _ I-Patient
to -X- _ I-Patient
35 -X- _ I-Patient
months -X- _ I-Patient
old -X- _ I-Patient
recruited -X- _ O
in -X- _ O
a -X- _ O
randomized -X- _ O
trial -X- _ O
of -X- _ O
zinc -X- _ O
supplementation -X- _ O
at -X- _ O
a -X- _ O
field -X- _ O
clinic -X- _ O
in -X- _ O
Bhaktapur -X- _ O
, -X- _ O
Nepal. -X- _ O
The -X- _ O
specimens -X- _ O
were -X- _ O
examined -X- _ O
for -X- _ O
respiratory -X- _ B-Intervention
syncytial -X- _ I-Intervention
virus -X- _ I-Intervention
( -X- _ I-Intervention
RSV -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
influenza -X- _ I-Intervention
virus -X- _ I-Intervention
type -X- _ I-Intervention
A -X- _ I-Intervention
( -X- _ I-Intervention
InfA -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
B -X- _ I-Intervention
( -X- _ I-Intervention
InfB -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
parainfluenza -X- _ I-Intervention
virus -X- _ I-Intervention
types -X- _ I-Intervention
1 -X- _ I-Intervention
, -X- _ I-Intervention
2 -X- _ I-Intervention
and -X- _ I-Intervention
3 -X- _ I-Intervention
( -X- _ I-Intervention
PIV1 -X- _ I-Intervention
, -X- _ I-Intervention
PIV2 -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
PIV3 -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
human -X- _ I-Intervention
metapneumovirus -X- _ I-Intervention
( -X- _ I-Intervention
hMPV -X- _ I-Intervention
) -X- _ I-Intervention
using -X- _ O
a -X- _ O
multiplex -X- _ O
reverse -X- _ O
transcriptase -X- _ O
polymerase -X- _ O
chain -X- _ O
reaction -X- _ O
( -X- _ O
PCR -X- _ O
) -X- _ O
assay. -X- _ O
RESULTS -X- _ O
: -X- _ O
We -X- _ O
identified -X- _ B-Outcome
919 -X- _ I-Outcome
virus -X- _ I-Outcome
isolates -X- _ I-Outcome
in -X- _ I-Outcome
887 -X- _ I-Outcome
( -X- _ I-Outcome
40.0 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
2,219 -X- _ I-Outcome
NPA -X- _ I-Outcome
specimens -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
valid -X- _ I-Outcome
PCR -X- _ I-Outcome
result -X- _ I-Outcome
, -X- _ I-Outcome
of -X- _ I-Outcome
which -X- _ I-Outcome
334 -X- _ I-Outcome
( -X- _ I-Outcome
15.1 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
yielded -X- _ I-Outcome
RSV -X- _ I-Outcome
, -X- _ I-Outcome
164 -X- _ I-Outcome
( -X- _ I-Outcome
7.4 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
InfA -X- _ I-Outcome
, -X- _ I-Outcome
129 -X- _ I-Outcome
( -X- _ I-Outcome
5.8 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
PIV3 -X- _ I-Outcome
, -X- _ I-Outcome
98 -X- _ I-Outcome
( -X- _ I-Outcome
4.4 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
PIV1 -X- _ I-Outcome
, -X- _ I-Outcome
93 -X- _ I-Outcome
( -X- _ I-Outcome
4.2 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
hMPV -X- _ I-Outcome
, -X- _ I-Outcome
84 -X- _ I-Outcome
( -X- _ I-Outcome
3.8 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
InfB -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
17 -X- _ I-Outcome
( -X- _ I-Outcome
0.8 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
PIV2. -X- _ I-Outcome
CAP -X- _ B-Patient
occurred -X- _ O
in -X- _ O
an -X- _ O
epidemic -X- _ O
pattern -X- _ O
with -X- _ O
substantial -X- _ O
temporal -X- _ O
variation -X- _ O
during -X- _ O
the -X- _ O
three -X- _ O
years -X- _ O
of -X- _ O
study. -X- _ O
The -X- _ O
largest -X- _ O
peaks -X- _ O
of -X- _ O
pneumonia -X- _ B-Patient
occurrence -X- _ O
coincided -X- _ O
with -X- _ O
peaks -X- _ O
of -X- _ O
RSV -X- _ O
infection -X- _ O
, -X- _ O
which -X- _ O
occurred -X- _ O
in -X- _ O
epidemics -X- _ O
during -X- _ O
the -X- _ O
rainy -X- _ O
season -X- _ O
and -X- _ O
in -X- _ O
winter. -X- _ O
The -X- _ B-Outcome
monthly -X- _ I-Outcome
number -X- _ I-Outcome
of -X- _ I-Outcome
RSV -X- _ I-Outcome
infections -X- _ I-Outcome
was -X- _ I-Outcome
positively -X- _ I-Outcome
correlated -X- _ I-Outcome
with -X- _ I-Outcome
relative -X- _ I-Outcome
humidity -X- _ I-Outcome
( -X- _ I-Outcome
r -X- _ I-Outcome
( -X- _ I-Outcome
s -X- _ I-Outcome
) -X- _ I-Outcome
= -X- _ I-Outcome
0.40 -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.01 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
not -X- _ I-Outcome
with -X- _ I-Outcome
temperature -X- _ I-Outcome
or -X- _ I-Outcome
rainfall. -X- _ I-Outcome
An -X- _ O
hMPV -X- _ O
epidemic -X- _ O
occurred -X- _ O
during -X- _ O
one -X- _ O
of -X- _ O
the -X- _ O
three -X- _ O
winter -X- _ O
seasons -X- _ O
and -X- _ O
the -X- _ O
monthly -X- _ O
number -X- _ O
of -X- _ O
hMPV -X- _ O
cases -X- _ O
was -X- _ O
also -X- _ O
associated -X- _ O
with -X- _ O
relative -X- _ O
humidity -X- _ O
( -X- _ O
r -X- _ O
( -X- _ O
s -X- _ O
) -X- _ O
= -X- _ O
0.55 -X- _ O
, -X- _ O
P -X- _ O
= -X- _ O
0.0005 -X- _ O
) -X- _ O
. -X- _ O
CONCLUSION -X- _ O
: -X- _ O
Respiratory -X- _ B-Outcome
RNA -X- _ I-Outcome
viruses -X- _ I-Outcome
were -X- _ I-Outcome
detected -X- _ I-Outcome
from -X- _ I-Outcome
NPA -X- _ I-Outcome
in -X- _ I-Outcome
40 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
CAP -X- _ I-Outcome
cases -X- _ I-Outcome
in -X- _ I-Outcome
our -X- _ I-Outcome
study. -X- _ I-Outcome
The -X- _ I-Outcome
most -X- _ I-Outcome
commonly -X- _ I-Outcome
isolated -X- _ I-Outcome
viruses -X- _ I-Outcome
were -X- _ I-Outcome
RSV -X- _ I-Outcome
, -X- _ I-Outcome
InfA -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
PIV3. -X- _ I-Outcome
RSV -X- _ O
infections -X- _ O
contributed -X- _ O
substantially -X- _ O
to -X- _ O
the -X- _ O
observed -X- _ O
CAP -X- _ O
epidemics. -X- _ O
The -X- _ O
occurrence -X- _ O
of -X- _ O
viral -X- _ O
CAP -X- _ O
in -X- _ O
this -X- _ O
community -X- _ O
seemed -X- _ O
to -X- _ O
reflect -X- _ O
more -X- _ O
or -X- _ O
less -X- _ O
overlapping -X- _ O
micro-epidemics -X- _ O
with -X- _ O
several -X- _ O
respiratory -X- _ O
viruses -X- _ O
, -X- _ O
highlighting -X- _ O
the -X- _ O
challenges -X- _ O
of -X- _ O
developing -X- _ O
and -X- _ O
implementing -X- _ O
effective -X- _ O
public -X- _ O
health -X- _ O
control -X- _ O
measures -X- _ O
. -X- _ O

